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Abstract 
Purpose: To evaluate the influence of bevacizumab on intratumor 
oxygenation status and lung metastasis following radiotherapy, 
specifically with reference to the response of quiescent (Q) cell 
populations within irradiated tumors. 
Materials and Methods: B16-BL6 melanoma tumor-bearing C57BL/6 mice were 
continuously given 5-bromo-2’-deoxyuridine (BrdU) to label all 
proliferating (P) cells. They received -ray irradiation following 
treatment with the acute hypoxia-releasing agent nicotinamide or local 
hyperthermia at mild temperatures (MTH) with or without the 
administration of bevacizumab under aerobic conditions or totally 
hypoxic conditions achieved by clamping the proximal end of the tumors. 
Immediately after the irradiation, cells from some tumors were isolated 
and incubated with a cytokinesis blocker. The responses of the Q and 
total (= P + Q) cell populations were assessed based on the frequency 
of micronuclei using immunofluorescence staining for BrdU. In other 
tumor-bearing mice, 17 days after irradiation, macroscopic lung 
metastases were enumerated. 
Results: Three days after bevacizumab administration, acute 
hypoxia-rich total cell population in the tumor showed the remarkably 
enhanced radio-sensitivity to -rays, and the hypoxic fraction (HF) was 
reduced, even after MTH treatment. However, the HF was not reduced after 
nicotinamide treatment. With or without -ray irradiation, bevacizumab 
administration showed some potential to reduce the number of lung 
metastases as well as nicotinamide treatment. 
Conclusion: Bevacizumab has the potential to reduce the 
perfusion-limited acute hypoxia and some potential to cause the decrease 
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Introduction 
It was believed that antiangiogenic therapy prevents the tumor 
vascular growth and proliferation, thus depriving the tumor of oxygen 
and nutrients necessary for survival [1]. Subsequent study, however, 
suggested that antiangiogenic therapy may also “normalize” the tumor 
vasculature for a short period of time, thereby providing a window of 
opportunity for improved drug delivery and enhanced sensitivity to 
radiation [1,2]. Tumor hypoxia results from either limited oxygen 
diffusion (chronic hypoxia) or limited perfusion (acute hypoxia) [3]. 
Further, it was reported that acute and cyclic, but not chronic, hypoxia 
significantly increased the number of spontaneous lung metastases, and 
that this effect was due to the influence of acute hypoxia treatment 
on the primary tumor [4,5] 
Here, we tried to analyze on hypoxia in solid tumors after the 
administration of the vascular endothelial growth factor (VEGF) 
inhibitor bevacizumab, using the acute hypoxia-releasing agent 
nicotinamide combined with -ray irradiation, in terms of both local 
tumor response and lung metastasis compared with irradiation combined 
with mild temperature hyperthermia (MTH), already shown to have the 
potential to release tumor cells from diffusion-limited chronic hypoxia 
[6,7]. In addition, concerning the local tumor response, the effect 
not only on the total (= proliferating (P) + quiescent (Q)) tumor cell 
population but also on the Q cell population was evaluated using our 
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Materials and Methods 
Mice and tumors 
B16-BL6 murine melanoma cells (Institute of Development, Aging and 
Cancer, Tohoku University) derived from C57BL/6 mice were maintained 
in vitro in RPMI-1640 medium supplemented with 10 % fetal bovine serum. 
Tumor cells (1.25 x 10
5
) were inoculated subcutaneously into the left 
hind leg of 8-week-old syngeneic female C57BL/6 mice (Japan Animal Co., 
Ltd., Osaka, Japan). Eighteen days later, the tumors, approximately 
7 mm in diameter, were employed for the cytotoxic treatment, and the 
body weight of the tumor-bearing mice was 20.1 ± 2.1 (Mean ± SD) g. 
Mice were handled according to the Recommendations for Handling of 
Laboratory Animals for Biomedical Research, compiled by the Committee 
on Safety Handling Regulations for Laboratory Animal Experiments at 
our university. The p53 of B16-BL6 tumor cells is the wild type [9]. 
Labeling with 5-bromo-2’-deoxyuridine (BrdU) 
Twelve days after the inoculation, mini-osmotic pumps (Durect 
Corporation, Cupertino, CA) containing BrdU dissolved in physiological 
saline (250 mg/ml) were implanted subcutaneously into the animals’ backs 
for 6 days to label all P cells. The percentage of labeled cells after 
the continuous treatment with BrdU reached a plateau at this stage. 
Therefore, tumor cells not incorporating BrdU after continuous labeling 
were regarded as Q cells. 
Treatment 
Fifteen days after the tumor cell inoculation, bevacizumab (a 
humanized monoclonal antibody against VEGF, Roche) dissolved in 
physiological saline was intravenously administered at a dose of 10 
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shown to induce the period of vascular normalization in B16-F10 murine 
melanoma tumors originating from B16-F1 murine melanoma cells [10]. 
Thus, in B16-BL6 tumors also originating from B16-F1 murine melanoma 
cells, bevacizumab was also thought to work the same as in B16-F10 tumors. 
Three days later (=18 days after inoculation, on day 18), the percentages 
of labeled cells after the continuous administration of BrdU for 6 days 
were 60.1 ± 6.8 % and 54.3 ± 6.0 % treated with bevacizumab and those 
not, respectively. Solid tumors grown in the left hind legs of mice 
were irradiated with a cobalt-60 -ray irradiator at 2.5 Gy/min on day 
18. Lead blocks were used to avoid irradiating other body parts. For 
irradiation, the animal was held in a specially designed device made 
of acrylic resin with the tail firmly fixed with adhesive tape under 
no anesthetic. 
Some tumor-bearing mice received an intraperitoneal administration 
of nicotinamide (1000 mg/kg) dissolved in physiological saline 1 hour 
before the irradiation. Others were subjected to local mild temperature 
hyperthermia (MTH) at 40°C for 60 min by immersing the implanted tumor 
in a water bath immediately before the irradiation [11]. Temperatures 
at the tumor center equilibrated within 3 to 4 min after immersion in 
the water bath and remained 0.2-0.3°C below the bath’s temperature. 
The water bath’s temperature was maintained at 0.3°C above the desired 
tumor temperature [11]. Some tumors implanted in other tumor-bearing 
mice were made totally hypoxic by clamping the proximal end of the tumors 
5 min before the irradiation, as reported previously [12]. The tumors 
were kept entirely hypoxic during the irradiation. This clamping method 
did not influence cell survival or the levels of micronuclei. 
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Each treatment group also included mice not pretreated with BrdU. 
Immunofluorescence staining of BrdU-labeled cells and micronucleus (MN) 
assay 
Immediately after irradiation, some tumors excised from the mice 
given BrdU were minced and trypsinized (0.05% trypsin and 0.02% 
ethylenediamine-tetraacetic acid (EDTA) in phosphate-buffered saline 
[PBS], 37 °C, 15 min). Tumor cell suspensions were incubated for 72 
hours in tissue culture dishes containing complete medium and 1.0 µg/ml 
of cytochalasin-B to inhibit cytokinesis while allowing nuclear 
division. The cultures were trypsinized, and cell suspensions were fixed 
and resuspended with cold Carnoy’s fixative (ethanol:acetic acid = 3:1 
in volume). The suspension was placed on a glass microscope slide, dried 
at room temperature and treated with 2 M hydrochloric acid for 60 min 
at room temperature to dissociate the histones and partially denature 
the DNA. The slides were immersed in borax-borate buffer (pH 8.5) to 
neutralize the acid. BrdU-labeled tumor cells were detected by indirect 
immunofluorescence staining using a monoclonal anti-BrdU antibody 
(Becton Dickinson, San Jose, CA) and a fluorescein isothiocyanate 
(FITC)-conjugated antimouse IgG antibody (Sigma, St. Louis, MO). To 
distinguish the tumor cells between stained with and without 
green-emitting FITC and observe them separately, cells on the slides 
were treated with red-emitting propidium iodide (PI, 2 µg/ml in PBS) 
as a background staining and monitored under a fluorescence microscope. 
The MN frequency in cells not labeled with BrdU could be examined 
by counting the micronuclei in the binuclear cells that showed only 
red fluorescence. The MN frequency was defined as the ratio of the number 
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cells observed [8]. 
The ratios obtained in tumors not pretreated with BrdU indicated 
the MN frequency at all phases in the total tumor cell population. More 
than 300 binuclear cells were counted to determine the MN frequency. 
Clonogenic cell survival assay 
The clonogenic cell survival assay was also performed for the 
implanted tumors in mice given no BrdU using an in vivo-in vitro assay 
method immediately after irradiation. Tumors were excised, weighed, 
minced, and disaggregated by stirring for 20 min at 37 °C in PBS 
containing 0.05 % trypsin and 0.02% EDTA. The cell yield was 1.2 ± 0.4 
x 10
7
/g tumor weight. Appropriate numbers of viable tumor cells from 
the single cell suspension were plated on 60 or 100 mm tissue culture 
dishes, and, 12 days later, colonies were fixed with ethanol, stained 
with Giemsa, and counted. For the tumors that received no irradiation, 
the plating efficiencies for the total tumor cell populations and the 
MN frequencies for the total and Q cell populations are shown in Table 
1. The plating efficiency indicates the percentage of cells seeded that 
grow into colonies when the tumors received no irradiation. The fraction 
of cells surviving a given dose is determined by counting the number 
of macroscopic colonies as a fraction of the number of cells seeded, 
followed by allowance, that is, dividing by the plating efficiency. 
As stated above, the MN frequencies for Q cells were obtained from 
unlabeled tumor cells after continuous BrdU labeling. The MN frequencies 
and surviving fractions (SFs) for total cell populations were obtained 
from cells in tumors not pretreated with BrdU. Thus, no interaction 
between BrdU and -ray irradiation could be observed on the values of 
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Measurement of the hypoxic fraction (HF) in B16-BL6 tumors 
The MN frequency in tumor cells not labeled with BrdU (= Q cells) 
were translated to the surviving fraction (SF), using the regression 
line for the relationship between the normalized MN frequency and the 
SF determined for the total cell populations in tumors from mice that 
were not pretreated with BrdU [6,8]. 
To determine the HF of the tumors, the paired survival curve method 
was employed using the values of the SFs for more than 16 Gy [5,13]. 
The best linear parallel lines were fitted to the dose-survival curves 
under both aerobic and hypoxic conditions by least squares regression, 
and the HFs were determined from the vertical displacement of the 
parallel lines [6,7,8]. 
Growth of B16-BL6 tumors 
After irradiation with -rays at a dose of 0 or 16 Gy on the 18th 
day after inoculation with or without treatment with bevacizumab, 
nicotinamide, or MTH, the size of the tumors implanted in the left hind 
legs of some tumor-bearing mice was checked 2-3 times a week for about 
20 days. Tumor volume was calculated using the formula: V = /6 x a x 
b
2
, where a and b are respectively the longest and shortest diameters 
of the tumor measured with calipers. There was no significant difference 
in tumor growth between the non-irradiated tumors treated with the 
intravenous administration of bevacizumab on day 15 and those not. 
Metastasis assessment 
Seventeen days after irradiation (= 35 days after the inoculation 
of B16-BL6 melanoma cells), the tumor-bearing mice were killed by 
cervical dislocation, and their lungs were removed, briefly washed with 
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overnight (Sigma), and stored in buffered formalin 10 % (Sigma) until 
metastases were counted. Macroscopically visible metastases were 
counted under a dissection microscope [14]. Eighteen days after the 
inoculation and immediately before -ray irradiation with or without 
bevacizumab, nicotinamide, or MTH, the numbers of macroscopic lung 
metastases were also counted as background data. The numbers obtained 
were 5.5 ± 1.8 and 7.5 ± 2.2 with and without the intravenous 
administration of bevacizumab on day 15, respectively. 
Data analysis and statistics 
Three mice with a tumor in the left hind leg were used to assess 
each set of conditions and each experiment was repeated three times. 
Namely, nine mice were used for each set of conditions. To examine the 
differences between pairs of values, Student’s t-test was used when 
variances of the two groups could be assumed to be equal; otherwise 
the Welch t-test was used. p-Values are from two-sided tests. The data 
of cell survival and MN frequencies were fitted to the linear quadratic 
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Results 
Table 1 shows the plating efficiencies for the total tumor cell 
population and the MN frequencies without -ray irradiation for the total 
and Q cell populations. The Q cell population showed significantly 
higher MN frequencies than the total cell population under each set 
of conditions. 
Figure 1 shows cell survival curves for the total cell population 
as a function of the dose of -rays with or without bevacizumab, 
nicotinamide, or MTH. Figures 2 shows normalized MN frequencies as a 
function of irradiated dose with or without bevacizumab, nicotinamide, 
or MTH in the total (left panels) and Q (right panels) tumor cell 
populations. The normalized MN frequency was the MN frequency in tumors 
that received -ray irradiation minus that in tumors that did not. 
Overall, the normalized MN frequencies were significantly smaller in 
Q cells than the total cell population (p < 0.05). 
To estimate the radio-enhancing effect of bevacizumab, 
nicotinamide, or MTH in both the total and Q cell populations compared 
with irradiation only, the data shown in Figs. 1 and 2 were used (Table 
2). In both cell populations, each combined treatment significantly 
enhanced the radio-sensitivity compared with irradiation only (p < 0.05). 
Nicotinamide only, bevacizumab only, and bevacizumab + nicotinamide 
significantly enhanced the radio-sensitivity of total cell populations 
compared with Q cell populations (p < 0.05). In contrast, MTH affected 
the Q cell populations more than total cell populations. In the total 
cell population, the addition of bevacizumab to MTH significantly 
increased the radio-enhancing effect (p < 0.05). In the Q cell population, 
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(p < 0.05). 
To examine the difference in radio-sensitivity between the total 
and Q cell populations, dose-modifying factors, were calculated using 
the data in Figs 1 and 2 (Table 3). The difference in radio-sensitivity, 
especially without bevacizumab, was widened with nicotinamide and 
reduced with MTH. However, the difference under irradiation after MTH 
was significantly enlarged with bevacizumab (p < 0.05). In contrast, 
the difference under irradiation only and irradiation after 
nicotinamide administration was not changed very much with bevacizumab. 
For each set of irradiation conditions, the regression lines for 
the relationship between the normalized MN frequency and the clonogenic 
SF determined for the total tumor cell population were found to be 
statistically identical. Thus, a regression line was calculated from 
pooled data for all sets of conditions, and found to have a significant 
positive correlation (p < 0.001) (Fig. 3). The normalized MN frequency 
of Q cells was translated to the clonogenic SF of Q cells, using the 
regression line determined for the total tumor cell population. 
Based on directly determined clonogenic SFs of the total tumor cell 
populations, the HF of total cells was determined for all conditioned 
tumors except totally hypoxic tumors (Table 4). Based on the clonogenic 
SFs of Q cell populations determined as shown above, the HF of Q cells 
was determined except for totally hypoxic tumors (Table 4). Overall, 
the values were significantly larger for Q cells than the total cells 
under each set of conditions (p < 0.05). Without bevacizumab, the size 
of the HF was significantly reduced in the following order: without 
MTH or nicotinamide > with MTH > with nicotinamide in the total cell 
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MTH in the Q cell population. With bevacizumab, in both populations, 
the further combination with MTH significantly decreased the size of 
the HF (p < 0.05). Similarly, with MTH, in both populations, the further 
combination with bevacizumab significantly decreased the size of the 
HF (p < 0.05). In the total cell population, bevacizumab significantly 
decreased the size of the HF (p < 0.05) compared with no combination. 
Figure 4 shows tumor growth curves after irradiation with or without 
treatment with bevacizumab, nicotinamide, or MTH 18 days after the tumor 
cell inoculation. To evaluate tumor growth, the period required for 
each tumor to become three times as large as on day 18 was obtained 
using the data shown in Fig. 4 (Table 5). Without irradiation, with 
or without bevacizumab, there was no significant difference in the 
period among without nicotinamide or MTH, with nicotinamide, and with 
MTH. With irradiation at a dose of 16 Gy, the period required was 
significantly prolonged (p < 0.05). Without bevacizumab, the period 
was significantly prolonged in combination with nicotinamide or MTH, 
especially with nicotinamide (p < 0.05). With bevacizumab, the period 
was significantly extended with MTH (p < 0.05). For irradiation only 
and irradiation after MTH, the period was also significantly prolonged 
in combination with bevacizumab (p < 0.05). 
Figure 5 shows the numbers of lung metastases on day 35 after 
inoculation as a function of the dose of -rays with or without 
bevacizumab, nicotinamide, or MTH. Without irradiation, irrespective 
of bevacizumab combination, nicotinamide and MTH seemed to decrease 
and increase the numbers of macroscopic metastases, respectively. With 
irradiation, as the delivered dose of -rays increased, the numbers 
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all the curves, no apparent radio-sensitizing or -protecting effect 
was observed in terms of the numbers of lung metastases. However, at 
the doses of 8 and 16 Gy, bevacizumab combination seemed to decrease 
the numbers a little. 
The numbers of lung metastases from the local tumors that received 
-rays under each irradiation condition which produced an identical SF 
of 0.05 as an initial effect, were estimated using the data shown in 
Fig. 5 (Table 6). Irrespective of bevacizumab combination, irradiation 
combined with nicotinamide resulted in smaller numbers than any other 
combination. Irrespective of nicotinamide or MTH combination, the 
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Discussion 
Perfusion-related (acute) hypoxia is caused by inadequate blood 
flow in tissues. Tumor microvasculatures frequently have severe 
structural and functional abnormalities, such as a disorganized 
vascular network, dilations, an elongated and tortuous shape, an 
incomplete endothelial lining, a lack of physiological/pharmacological 
receptors, an absence of flow regulation, and intermittent stasis [16]. 
Perfusion-related O
2
 delivery leads to ischemic hypoxia, which is often 
transient. Thus, acute hypoxic areas are distributed throughout the 
tumor depending on these causative factors [3,5,13]. Nicotinamide, a 
vitamin B
3
 analogue, prevents these transient fluctuations in tumor 
blood flow that lead to the development of acute hypoxia [17]. 
Diffusion-related (chronic) hypoxia is caused by an increase in 
diffusion distances with tumor expansion. This results in an inadequate 
O
2
 supply for cells distant (>70μm) from the nutritive blood vessels. 
Diffusion-related hypoxia may also be caused by deterioration of 
diffusion “geometry,” for example, concurrent versus countercurrent 
blood flow within the tumor microvessel network [5,13]. MTH before 
irradiation decreased the HF, even combined with nicotinamide 
administration. In contrast, MTH did not decrease the HF when 
tumor-bearing mice were placed in a circulating carbogen (95% O2 / 5% 
CO2) chamber during irradiation [6]. Thus, MTH was shown to increase 
the tumor response to radiation by improving tumor oxygenation through 
an increase in tumor blood flow [18], thereby preferentially overcoming 
chronic hypoxia rather than acute hypoxia. 
As shown in Fig. 3, the normalized MN frequency can fully reflect 
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a statistically significant positive correlation with SF. Actually, 
similar finding was already shown in the previous report [19]. In B16-BL6 
tumors, the radio-sensitization was a little higher with nicotinamide 
than MTH in the total cell population, and a little larger with MTH 
than nicotinamide in Q cells (Figs. 1 and 2, Table 2). Further, 
nicotinamide and MTH remarkably reduced the size of the HF in total 
and Q cell populations, respectively (Table 4). These findings supported 
that the HFs in the total and Q cell populations of B16-BL6 tumors, 
like SCC VII tumors, are predominantly composed of acute and chronic 
HFs, respectively [6]. 
The decrease in the HF induced by combining bevacizumab with MTH 
was more remarkable than that achieved by combining bevacizumab with 
nicotinamide treatment in both total and Q cell populations (Table 4). 
In both bevacizumab and/or nicotinamide and bevacizumab and/or MTH, 
bevacizumab alone decreased the HF more markedly in total than in Q 
cell population (Table 4). These results indicated that bevacizumab 
preferentially oxygenated the acutely HF rather than the chronically 
HF in this tumor. In other words, the HF in the tumor treated with 
bevacizumab may be preferentially composed of the chronic HF. It is 
true that bevacizumab was also shown to decrease the size of the 
chronically HF to some degree [10], but the reduction of acute hypoxia 
was thought to be much more remarkable than that of chronic hypoxia, 
based on our findings observed here. Meanwhile, the changes in tumor 
growth as a whole (Fig. 4, Table 5) were reasonably consistent with 
and well supported the changes in the radio-sensitivity of total tumor 
cell populations in cell survival curves (Fig. 1) and dose-response 
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The recombinant humanized monoclonal antibody, bevacizumab is 
composed of the human IgG1 framework regions and the antigen-binding 
regions from the murine IgG1 anti-human VEGF monoclonal antibody [20]. 
The antibody can be cross-reactive with other species, as shown here. 
In previous animal experiments, tumor hypoxia decreased 2 days after 
antiangiogenic treatment such as vascular endothelial growth factor 
(VEGF)-blocking therapy, was almost abolished by day 5, and increased 
again by day 8 [2,10]. In addition to reducing hypoxia, antiangiogenic 
treatment is thought to be associated with the recruitment of pericytes 
– cells that help shore up vessel walls – to the tumor blood vessels, 
which stabilize the leaky and dilated vasculature, common 
characteristics of tumor vessels [21]. The pericyte-covered vessels 
were also reported to decrease in number by day 8 [20]. Vascular 
normalization including the recruitment of pericytes is thought to occur 
2 to 5 days after the blocking of VEGF [1,3]. During this window some 
2 to 5 days after the blocking of VEGF, pericyte coverage of tumor vessels 
[1,2] and a decrease in tumor vessel permeability and interstitial fluid 
pressure [22] occur, resulting in normalization of tumor vessels leading 
to the release from acute hypoxia. 
The presence of Q cells is probably due, at least in part, to hypoxia 
and the depletion of nutrition, a consequence of poor vascular supply 
[1.13,22]. As a result, Q cells are viable and clonogenic, but have 
ceased dividing. This might promote the formation of micronuclei at 
0 Gy in Q tumor cells (Table 1). Q cells were shown to have significantly 
less radiosensitivity than the total cell population (p < 0.05) (Fig. 
2, Table 3). This means that more Q cells survive radiation therapy 
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outcome of radiotherapy for controlling local tumors. The difference 
in radiosensitivity between the total and Q cell populations was 
increased by adding bevacizumab (Table 3) because of the greater 
enhancement in radiosensitivity in the total than Q cell population 
through the release from acute hypoxia, except when combined with MTH 
(Table 2). Nicotinamide and MTH enhanced the radiosensitivity of the 
total and Q cell population at irradiation, leading to an increase and 
a decrease in the difference in radiosensitivity, respectively [6,7]. 
MTH was thought to be more useful than nicotinamide or bevacizumab 
because of the MTH induced-reduction of the difference in sensitivity 
between radiosensitive total and radioresistant Q cell populations. 
Hypoxia is suggested to enhance metastasis by increasing genetic 
instability [5]. Acute but not chronic hypoxia increased the number 
of macroscopic metastases in mouse lungs [4,5]. We recently reported 
the significance of the injection of an acute hypoxia-releasing agent, 
nicotinamide, into tumor-bearing mice as a combined treatment with -ray 
irradiation in terms of repressing lung metastasis [7]. With or without 
irradiation, nicotinamide and the VEGF blocking agent bevacizumab 
seemed to reduce the number of macroscopic lung metastases (Fig. 5, 
Table 4). During the window of vascular normalization, acute hypoxia 
may be preferentially released and this release seems to be more 
important in suppressing metastasis from the primary tumor than is the 
release of cells from chronic hypoxia. Without irradiation, MTH seemed 
to increase the number of metastases, implying that the release from 
chronic hypoxia is not as important in repressing metastasis as the 
release from acute hypoxia. However, hyperthermia is not thought to 
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of -rays increased with irradiation, the number of macroscopic lung 
metastases decreased reflecting the decrease in the number of 
clonogenically viable tumor cells in the primary tumor (Fig. 5). 
Metastasis-repressing effect achieved through a reduction in the number 
of clonogenic tumor cells by irradiation is much greater than that 
achieved by reducing tumor cells from acute hypoxia. An acute 
hypoxia-releasing treatment such as the administration of nicotinamide 
and/or bevacizumab may be promising for reducing numbers of lung 
metastases. It was shown that control of the chronic hypoxia-rich Q 
cell population and the acute hypoxia-rich total cell population in 
the primary tumor can have the potential to give an impact to control 
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Table 1. 
 
Plating efficiency and micronucleus frequency at 0 Gy 
__________________________________________________________________ 
 Total cell population Quiescent cells 
__________________________________________________________________ 
<Plating efficiency (%)> 
Absolutely control 84.4 ± 8.2
a
 ---- 
Totally hypoxic 73.9 ± 7.3 ---- 
Nicotinamide only 81.4 ± 7.3 ---- 
MTH
b only 83.5 ± 8.7 ---- 
BV
c
 only 80.1 ± 8.0 ---- 
BV + nicotinamide 76.3 ± 7.8 ---- 
BV + MTH 78.4 ± 7.9 ---- 
<Micronucleus frequency> 
Absolutely control 0.050 ± 0.008 0.077 ± 0.009 
Totally hypoxic 0.069 ± 0.008 0.087 ± 0.007 
Nicotinamide only 0.057 ± 0.006 0.084 ± 0.009 
MTH only 0.054 ± 0.005 0.081 ± 0.009 
BV only 0.058 ± 0.007 0.083 ± 0.009 
BV + nicotinamide 0.068 ± 0.008 0.086 ± 0.010 
BV + MTH 0.069 ± 0.008 0.087 ± 0.010 
__________________________________________________________________ 
a; Mean ± standard error (n = 9) 









































































 due to combined treatment with 
bevacizumab, nicotinamide, or mild temperature hyperthermia 
__________________________________________________________________ 
   Total cell population Quiescent cells 
__________________________________________________________________ 
<Surviving fraction = 0.05> 
   + Nicotinamide  1.3 ± 0.1
b  ---- 
   + MTH
c
   1.1 ± 0.05
1
  ---- 
   + BV
d
 only   1.2 ± 0.1   ---- 
   + BV + Nicotinamide 1.25 ± 0.1  ---- 
   + BV + MTH   1.35 ± 0.1
1
  ---- 
<Normalized micronucleus frequency = 0.3>  
   + Nicotinamide  1.2 ± 0.1
2
  1.05 ± 0.05
2
 
   + MTH   1.05 ± 0.05
3,4
  1.25 ± 0.05
3
 
   + BV only   1.15 ± 0.05
5
  1.05 ± 0.05
5,6
 
   + BV + Nicotinamide 1.15 ± 0.05
7
  1.05 ± 0.05
7
 
   + BV + MTH   1.25 ± 0.1
4





; The ratio of the dose of radiation necessary to obtain each end-point 
without combined treatment to that needed to obtain each end-point 
with the combined treatment. 
b
; Mean ± standard error (n = 9) 
c; Mild temperature hyperthermia. 
d; Bevacizumab 
1,2,3,4,5,6,7
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Table 3. 
 
Dose-modifying factors for quiescent cells 




   Without Bevacizumab  With Bevacizumab 
__________________________________________________________________ 
<Normalized micronucleus frequency = 0.3> 
   Radiation only  1.7 ± 0.1
b,1,2
  1.75 ± 0.1 
   + Nicotinamide  1.9 ± 0.1
1
  1.85 ± 0.1 
   + MTH
c
   1.5 ± 0.1
2,3





; The ratio of the dose of radiation necessary to obtain each end-point 
in the quiescent cell population to that needed to obtain each 
end-point in the total tumor cell population. 
b
; Mean ± standard error (n = 9) 
c
; Mild temperature hyperthermia 
1,2,3
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Table 4. 
 
The sizes of the hypoxic fractions (%) 




 Without Bevacizumab With Bevacizumab 
__________________________________________________________________ 
<Total tumor cell population> 
Without nicotinamide or MTH 16.1 ± 2.8
b,1,2,3
 8.4 ± 1.7
1
 
With Nicotinamide 7.5 ± 1.6
2,4
 8.1 ± 1.7 
With MTH
c 11.5 ± 1.6
3,4,5
 6.3 ± 1.5
5
 
<Quiescent tumor cell population> 
Without nicotinamide or MTH 51.3 ± 5.5
6,7
 44.6 ± 5.3
8
 
With Nicotinamide 38.5 ± 6.4
6,9
 41.2 ± 6.5
10
 
With MTH 25.5 ± 3.4
7,9,11





; Based on the paired survival curve method using the dose-survival 
curves under both aerobic and hypoxic conditions for more than 16 
Gy. 
b
; Mean ± standard error (n = 9) 
c; Mild temperature hyperthermia. 
1,2,3,4,5,6,7,8,9,10,11
; The differences between two values were significant (p 
< 0.05). Overall, the values were significantly larger in Q cells 
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Table 5. 
 
The period (days) required for each tumor to become three times 
as large as on day 18 after tumor cell inoculation 
__________________________________________________________________ 
   Without Bevacizumab  With Bevacizumab 
__________________________________________________________________ 
<No irradiation> 
   No treatment  3.4 ± 0.6
a
  3.1 ± 0.5 
   + Nicotinamide  3.4 ± 0.6  3.3 ± 0.6 
   + MTH
b
   4.3 ± 0.9  3.6 ± 0.7 
<Irradiated dose = 16 Gy> 
   Radiation only  13.5 ± 2.0
1,2,3
  22.4 ± 1.4
1,4
 
   + Nicotinamide  24.7 ± 1.5
2
  23.7 ± 1.5 
   + MTH   20.7 ± 2.0
3,5





; Mean ± standard error (n = 9) 
b
; Mild temperature hyperthermia. 
1,2,3,4,5
; The differences between two values were significant (p < 0.05). 
Whether for irradiation only, irradiation plus nicotinamide, or 
irradiation plus MTH with or without bevacizumab, the differences 



































































Reducing intratumor acute hypoxia with bevacizumab/Page 28 
Table 6. 
 
The numbers of metastases from the irradiated tumors that received 




  Without Bevacizumab With Bevacizumab 
__________________________________________________________________ 
<Surviving fraction = 0.05> 
   Radiation only 14.9 11.8 
   + Nicotinamide 14.0 11.3 
   + MTH
b
  14.8 13.1 
__________________________________________________________________ 
a
; Using the data shown in Figure 5, the numbers of lung metastases 
were estimated from local tumors that received -ray doses with or 
without bevacizumab, nicotinamide, or mild temperature 
hyperthermia, which produced an identical surviving fraction of 
0.05 after in vivo-in vitro assays. 
b
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Figure legends 
Fig. 1 Cell survival curves for the total cell population from B16-BL6 
tumors irradiated with -rays with or without treatment with 
bevacizumab (BV), nicotinamide, or mild temperature 
hyperthermia (MTH) on day 18 after tumor cell inoculation. The 
clonogenic surviving fractions for irradiation under totally 
hypoxic conditions achieved by clamping the proximal end of the 
tumors are also shown. ,  irradiation only under aerobic 
conditions; ,  irradiation under aerobic conditions 
following nicotinamide treatment; ,  irradiation under 
aerobic conditions following MTH; , ,  irradiation 
without bevacizumab; , ,  irradiation with 
bevacizumab;  irradiation under totally hypoxic conditions. 
Bars represent standard errors (n = 9). 
Fig. 2 Dose response curves of the normalized micronucleus frequency 
for total (left panels) and quiescent (right panels) cell 
populations from B16-BL6 tumors irradiated with or without 
bevacizumab (BV) in combination with nicotinamide (upper 
panels) or mild temperature hyperthermia (MTH) (lower panels) 
on day 18 after inoculation. Symbols are as in Figure 1. Bars 
represent standard errors (n = 9). 
Fig. 3 The correlation between the normalized micronucleus frequency 
and the surviving fraction of the total cell population for each 
tumor under each set of treatment conditions. The regression 
line had a significant positive correlation: ln Y = - 5.11 X 
(r - -0.96, p < 0.001). Symbols are as in Figure 1. Bars represent 
standard errors (n = 9). 
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with or without treatment with bevacizumab (BV), nicotinamide, 
or mild temperature hyperthermia (MTH) on day 18 after tumor 
cell inoculation. Tumor growth was determined by comparing tumor 
volume with that on -ray irradiation. ,  irradiation only 
under aerobic conditions; ,  irradiation under aerobic 
conditions following nicotinamide treatment; ,  
irradiation under aerobic conditions following MTH; , , 
 without irradiation; , ,  with irradiation at a dose 
of 16 Gy;  irradiation without bevacizumab;  
irradiation with bevacizumab . Bars represent standard errors 
(n = 9). 
Fig. 5 Counted numbers of macroscopic metastases in the lung on day 
35 after tumor cell inoculation as a function of the dose of 
-rays with or without treatment with bevacizumab (BV), 
nicotinamide, or mild temperature hyperthermia (MTH) on day 18 
after tumor cell inoculation. ,  irradiation only under 
aerobic conditions; ,  irradiation under aerobic 
conditions following nicotinamide treatment; ,  
irradiation under aerobic conditions following MTH; , , 
 irradiation without bevacizumab; , ,  irradiation 
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